December 2025 – OncWonk – Dr Bier's Oncology Research Reviews

Soy Isoflavones in Integrative Oncology: Increased Efficacy and Decreased Toxicity of Cancer Therapy

December 31, 2025

| Cancer - Prostate, Cancers, Supplements

Comment: While the biomarker shifts and preclinical toxicity reductions in this review are biologically profound, it is always important to remember that mechanistic success rarely translates directly to human clinical outcomes. That being clear, on a risk-benefit assessment, there is no reason to not include genistein, and some clear signals to. The tangible significance of […]

Significance Testing

December 30, 2025

| No Comments

| Statistics

Concept: The P-Value (Hypothesis Testing) Statistical Concept Definition: The P-value is the probability of obtaining a result at least as extreme as the one observed, assuming that the null hypothesis is true (i.e., assuming there is truly no difference between the groups). It quantifies the strength of the evidence against the null hypothesis. Clinical Significance: […]

Confounding by Indication

December 27, 2025

| No Comments

| Statistics

Audio Overview: Statistical Concept Definition Confounding by indication (also known as “prognostic bias” or “susceptibility bias”) is a systematic error prevalent in observational research where the clinical reason for a treatment—the indication—is also a predictor of the outcome. In this scenario, the baseline risk of the patient, rather than the treatment itself, drives the observed […]

Attenuation of malignant phenotype of glioblastoma following a short course of the pro-oxidant combination of Resveratrol and Copper

December 25, 2025

| No Comments

| Cancer - Brain, Supplements

Comment: This pilot study offers a compelling glimpse into how targeting the tumor microenvironment (TME) through unconventional mechanisms can yield profound biological results. By utilizing a low-dose, pro-oxidant combination of Resveratrol and Copper, researchers were able to essentially “neutralize” the TME by deactivating cell-free chromatin particles. The downstream biochemical effects were remarkable: a highly significant […]

Thyroid hormone enhances estrogen-mediated proliferation and cell cycle regulatory pathways in steroid receptor-positive breast Cancer

December 24, 2025

| No Comments

| Cancer - Breast, Medications - General Pharmaceuticals

Comment: This study provides the critical ‘why’ behind the findings from this same groups earlier study. In that article, we highlighted that exogenous thyroid hormone is associated with significantly shortened survival in SR+ breast cancer patients. Now, this research explains elucidates the underlying mechanism: thyroid hormone essentially ‘hijacks’ the estrogen receptor, driving proliferation and rendering […]

Risk of Subsequent Primary Cancers in Thyroid Cancer Survivors according to the Dose of Levothyroxine: A Nationwide Cohort Study

December 24, 2025

| No Comments

| Cancers, Medications - General Pharmaceuticals

Comment: Yet another study challenging the safety profile of synthetic T4. The data here is sobering: thyroid cancer survivors on high-dose levothyroxine faced significantly higher risks of developing a second unrelated (not recurrence) cancer, particularly in the GI tract. With hazard ratios for pancreatic, liver cancers reaching nearly 2.5 and 2.0 respectively, this is a […]

Exogenous Thyroid Hormone Is Associated with Shortened Survival and Upregulation of High-Risk Gene Expression Profiles in Steroid Receptor-Positive Breast Cancers

December 24, 2025

| No Comments

| Cancer - Breast, Medications - General Pharmaceuticals

Comment: This paper serves as a major wake-up call regarding the risks of thyroid replacement in SR+ breast cancer, which compromises about 80% of cases. The mechanistic finding—that thyroid hormone can reverse Tamoxifen’s action from antagonist to agonist—is a critical piece of the puzzle explaining treatment failure. Furthermore, the observation that Aromatase Inhibitors also showed […]

Post-diagnosis supplement use and breast cancer prognosis in the After Breast Cancer Pooling Project

December 20, 2025

| No Comments

| Cancer - Breast, Supplements

Comment: Cancer survivors are still frequently told that they should avoid antioxidants due to the wholly theoretical risk that they might ‘rescue’ residual cancer cells. This large-scale analysis effectively dismantles that dogma. Instead of harm, we see a clear survival advantage—a 16% reduction in total mortality for those using antioxidants post-treatment. Whether it is the […]

Effect of High-Dose vs Standard-Dose Vitamin D3 Supplementation on Progression-Free Survival Among Patients With Advanced or Metastatic Colorectal Cancer – The SUNSHINE Randomized Clinical Trial

December 20, 2025

| No Comments

| Cancer - Colon, Supplements

Comment: These findings are another, again highlight the massive, untapped potential of nutritional synergy with conventional treatment. Adding just 4,000 IU of Vitamin D3 didn’t just improve serum levels,; it translated to a tangible clinical victory—a 36% reduction in the risk of progression or death. This indicates that Vitamin D acts as a ‘force multiplier’ […]

Impact of antioxidant supplementation on chemotherapeutic efficacy: a systematic review of the evidence from randomized controlled trials

December 20, 2025

| No Comments

| Cancers, Chemotherapy, Supplements

Comment: This systematic review serves as a definitive corrective to the long-standing dogma against concurrent antioxidant use with chemotherapy. Patients still come in being told that antioxidants might ‘rescue’ tumor cells from chemotherapy, almost completely from preclinical models. However, these findings remind us why Randomized Controlled Trials are the ultimate arbiter. When tested in actual […]